InvestorsObserver is giving Fate Therapeutics Inc (FATE) an Analyst Rating Rank of 20, meaning FATE is ranked higher by analysts than 20% of stocks. The average price target for FATE is $7.462 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating FATE a Buy today. Find out what this means to you and get the rest of the rankings on FATE!